The CXCR4 Antagonist AMD3100 Has Dual Effects, Initially Enhancing and Later Inhibiting Survival and Proliferation, in Myeloid Leukemia Cells in Vitro.

被引：0
|
作者：
Kim, Ha-Yon [1 ]
Hwang, Ji-Young [1 ]
Kim, Seong-Woo [1 ]
Yun, Gak-Won [1 ]
Yang, Young-Joon [1 ]
Lee, Hyo-Jin [1 ]
Jo, Deog-Yeon [1 ,2 ]
机构：
[1] Chungnam Natl Univ, Dept Internal Med, Sch Med, Div Hematol Oncol, Taejon, South Korea
[2] Chungnam Natl Univ, Canc Res Inst, Taejon, South Korea
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：685 / 686
页数：2
相关论文
共 50 条
  • [21] The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
    Philipp Berning
    Christiane Schaefer
    Dagmar Clemens
    Eberhard Korsching
    Uta Dirksen
    Jenny Potratz
    Cell Communication and Signaling, 16
  • [22] The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
    Berning, Philipp
    Schaefer, Christiane
    Clemens, Dagmar
    Korsching, Eberhard
    Dirksen, Uta
    Potratz, Jenny
    CELL COMMUNICATION AND SIGNALING, 2018, 16
  • [23] Blockade of CXCR4 by AMD3100 reduces homing and survival of plasma cells in lupus mice NZB/W
    Cheng, Q.
    Khodadadi, L.
    Taddeo, A.
    Winter, O.
    Hoyer, B.
    Radbruch, A.
    Hiepe, F.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 34 - 34
  • [24] The SDF-1/CXCR4 pathway is involved in the homing of chronic lymphocytic leukemia B cells and in their survival after migration into bone marrow stromal layers: inhibition by the CXCR4 antagonist (AMD3100)
    Lagneaux, L
    Delforge, A
    Dejeneffe, M
    Schols, D
    Bron, D
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (06) : 54 - 54
  • [25] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
    Arakaki, R
    Tamamura, H
    Premanathan, M
    Kanbara, K
    Ramanan, S
    Mochizuki, K
    Baba, M
    Fujii, N
    Nakashima, H
    JOURNAL OF VIROLOGY, 1999, 73 (02) : 1719 - 1723
  • [26] Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100
    Bonig, Halvard
    Chudziak, Doreen
    Priestley, Greg
    Papayannopoulou, Thalia
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (03) : 402 - 415
  • [27] The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Wang, Shan
    Wang, Xiaojiao
    Liu, Sha
    Zhang, Shengnan
    Wei, Xudong
    Song, Yongping
    Yin, Qingsong
    ONCOTARGETS AND THERAPY, 2020, 13 : 6583 - 6591
  • [28] The CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+cells than G-CSF
    Seeger, T
    Veldwijk, M
    Bridger, G
    Calandra, G
    Goldschmidt, H
    Ho, A
    Fruehauf, S
    BLOOD, 2005, 106 (11) : 558A - 558A
  • [29] The CXCR4 receptor antagonist AMD3100 does not prevent homing and engraftment of murine syngeneic bone marrow stem cells.
    van Os, R
    Schols, D
    Struyf, S
    De Clercq, E
    Willemze, R
    Fibbe, WE
    BLOOD, 2000, 96 (11) : 308B - 308B
  • [30] Comparison of the Response to the CXCR4 Antagonist AMD3100 during the Development of Retinal Organoids Derived from ES Cells and Zebrafish Retina
    Wu, Yihui
    Qiu, Jin
    Chen, Shuilian
    Chen, Xi
    Zhang, Jing
    Zhuang, Jiejie
    Liu, Sian
    Yang, Meng
    Zhou, Pan
    Chen, Haoting
    Yu, Keming
    Ge, Jian
    Zhuang, Jing
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
12345